The Healthcare Data

FDA Clears Pulse Biosciences to Begin nsPFA AFib Trial

Pulse Biosciences Secures FDA IDE Approval to Launch nsPFA Cardiac Surgery Study for Atrial Fibrillation Treatment Pulse Biosciences, Inc. (Nasdaq: PLSE), a medical technology company pioneering nonthermal ablation therapies through its proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) platform, has reached…